* Bio Rad Laboratories Inc BIO.N BIO is expected to show
a
fall in quarterly revenue when it reports results on February
15 for the period ending December 31 2023
* The Hercules California-based company is expected to
report a
6.2% decrease in revenue to $685.093 million from $730.29
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data. (Majority is on Net Revenue/ Net
sales basis)
* LSEG's mean analyst estimate for Bio Rad Laboratories Inc
is
for earnings of $2.82 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Bio Rad
Laboratories Inc is $400.00, above its last closing price
of $316.10.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 2.81 2.78 2.33 Missed -16.3
Jun. 30 2023 2.68 2.68 3.00 Beat 12
Mar. 31 2023 3.59 3.54 3.34 Missed -5.7
Dec. 31 2022 3.43 3.45 3.31 Missed -4
Sep. 2.83 2.78 2.60 Missed -6.5
30 2022
Jun. 30 2022 2.90 2.80 3.38 Beat 20.8
Mar. 31 2022 3.45 3.40 4.94 Beat 45.2
Dec. 31 2021 2.86 2.85 3.21 Beat 12.6
This summary was machine generated February 13 at 22:01 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)